# Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

> **NCT05205603** · PHASE4 · COMPLETED · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 438 (actual)

## Conditions studied

- Ulcerative Colitis
- Efficacy, Self
- Biologics
- Mesalazine

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Vedolizumab
- **DRUG:** Mesalazine

## Key facts

- **NCT ID:** NCT05205603
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-15
- **Primary completion:** 2024-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205603, "Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05205603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*